-- Novo Nordisk Stock Tumbles Monday to Its Lowest Point in Nearly 5 Years. Here's Why [Stocks Lose Ground Amid Tariff Uncertainty][Trump's 'Plan B' on Tariffs: More Tariffs][Economy Grew Far Less Than Expected in Q4][Inflation Likely to Keep Fed from Cutting Rates Soon]- Top StoriesWith Monday's drop, Novo Nordisk shares have lost more than half their value in the last 12 months.Kristian Tuxen Ladegaard Berg / NurPhoto / Getty ImagesClose### Key Takeaways- Novo Nordisk's CagriSema, its next-generation weig ...

Core Insights - Eli Lilly and Company has built up an inventory of $1.5 billion for its experimental oral weight-loss drug, orforglipron, in anticipation of an FDA decision expected in April, marking a significant increase from nearly $550 million last year [1] - The FDA has granted a fast-track review voucher for the weight-loss pill, potentially reducing the approval timeline to one or two months, compared to the usual 10 to 12 months for most new drugs [2] - Eli Lilly aims to have sufficient supply to launch the weight-loss pill across multiple countries simultaneously, pending U.S. approval [2] Financial Performance - Eli Lilly's stock has increased by 19.09% over the past year, with a recent rise of 2.27% to close at $1,038.27 [3] - Benzinga's Edge Rankings place Eli Lilly in the 90th percentile for quality and the 84th percentile for momentum, indicating strong performance relative to peers [3]

Core Insights - OneSource Specialty Pharma has received approval for its generic version of Ozempic in Saudi Arabia, allowing it to enter a significant market for type-2 diabetes and weight-loss drugs [1][2] - The partnership with Hikma Pharmaceuticals PLC aims to meet the rising demand for affordable generic drug alternatives in the Middle East and North Africa (MENA) region [3][4] Company Strategy - OneSource will manufacture semaglutide at its Bengaluru facility, while Hikma will leverage its commercial reach to enhance the drug's availability [3] - The collaboration with Hikma, the largest pharmaceutical company in the MENA region by sales, is expected to provide a strong platform for scaling access to this therapy [4] Market Dynamics - OneSource is preparing for a significant increase in demand for generic semaglutide as Novo Nordisk is set to lose patent exclusivity in over 80 countries this year [5] - The company is fast-tracking a $100 million capacity expansion to capitalize on the global boom in weight-loss drugs [5] Financial Performance - In Q3, OneSource's revenue fell 26% year-over-year to ₹290.3 crore ($33.1 million) due to delays in semaglutide approvals in Canada [6] - The company's EBITDA dropped 88%, with the EBITDA margin contracting to 6% from 36% a year earlier [6] - OneSource aims to achieve $500 million in revenue by FY28 [6]

Core Insights - Hims & Hers Health's stock dropped 25% after the company announced it would cease selling its compounded semaglutide weight-loss pill, just days after its launch, due to legal action from Novo Nordisk [1][1][1] - Novo Nordisk has filed a lawsuit against Hims & Hers, seeking to permanently ban the sale of unapproved compounded drugs that infringe on its patents and is pursuing damages [1][1][1] - Hims & Hers has faced significant stock depreciation, losing over 60% of its value in the past 12 months, while Novo Nordisk's shares have decreased by approximately 40% during the same period [1][1][1] Company Developments - Hims & Hers announced the discontinuation of its compounded weight-loss pill, which was marketed as having the same active ingredient as Novo Nordisk's Wegovy, following legal threats from Novo Nordisk [1][1][1] - The lawsuit from Novo Nordisk is described by Hims & Hers as a "blatant attack" on Americans who rely on compounded medications, indicating the company's intent to continue advocating for access to these treatments [1][1][1] Industry Context - The FDA has indicated plans to restrict the use of GLP-1 active ingredients in compounded weight-loss medications, specifically mentioning Hims & Hers in its statement [1][1][1] - Eli Lilly is anticipated to receive FDA approval for its own weight-loss pill later this year, which could further impact competition in the weight-loss drug market [1][1][1]

Core Viewpoint - Hims & Hers has abandoned its plan to offer a compounded version of the weight-loss drug Wegovy, following threats from the FDA and legal action from Novo Nordisk, the original manufacturer of Wegovy [1][1][1] Company Actions - Hims & Hers announced the decision to drop the compounded semaglutide pill just two days after its introduction, citing constructive conversations with industry stakeholders [1][1] - The company had initially planned to sell its version of Wegovy at a significantly lower price of $49 for the first month and $99 thereafter, compared to Novo's price of $149 per month [1][1][1] Regulatory Environment - The FDA indicated plans to restrict access to the active ingredients necessary for compounding popular GLP-1 drugs, which include Wegovy, Ozempic, and Zepbound [1][1] - The FDA has stated that GLP-1 drugs are no longer in shortage as of 2024, which is expected to end the practice of compounding these medications [1][1] Market Context - Hims & Hers, along with other companies, entered the multibillion-dollar market for obesity medications, driven by the high demand for GLP-1 drugs [1][1] - The compounded version of the semaglutide pill that Hims planned to sell was not FDA-approved and had not undergone trials to prove its effectiveness [1][1]

Core Viewpoint - Hims & Hers launched a once-a-day weight-loss pill as a cheaper alternative to Novo Nordisk's Wegovy but decided to stop selling it shortly after due to industry feedback and regulatory scrutiny [1][2]. Company Actions - Hims & Hers initially claimed that the compounded semaglutide pill met "rigorous clinical standards" upon its launch [2]. - The company announced its decision to cease offering the treatment after engaging in discussions with industry stakeholders [2]. Regulatory Environment - The FDA issued a statement indicating its intention to restrict certain ingredients in non-FDA-approved compounded drugs, specifically targeting companies like Hims & Hers [8]. - The FDA warned that failure to address violations related to unapproved compounded GLP-1 products could lead to legal actions, including seizure and injunction [8]. Industry Context - Novo Nordisk revitalized the weight-loss medication market with its Ozempic product in 2022, which was initially marketed for type 2 diabetes but later prescribed for obesity [9]. - Following the success of Ozempic, Novo Nordisk developed Wegovy, specifically for weight management, which included an oral version launched in January [9]. - The surge in demand for weight-loss medications has led many health-focused companies to create off-brand versions to capitalize on the market [10].

Core Viewpoint - Hims & Hers Health has launched a new weight-loss pill that contains the same active ingredient as Novo Nordisk's Wegovy, leading to significant stock price movements among major weight-loss drugmakers [1] Company Impact - Shares of Eli Lilly and Novo Nordisk fell approximately 8% following the announcement of Hims & Hers' new pill, while Hims & Hers shares initially rose nearly 14% before closing down nearly 4% [1] - Hims & Hers' new pill is priced at $49 per month for five months, significantly lower than Wegovy, which costs $149 for self-pay patients [1] - Novo Nordisk has indicated plans to pursue legal action against Hims & Hers regarding the new product [1] Industry Context - The announcement comes after Eli Lilly and Novo Nordisk reported their latest earnings, with Novo Nordisk warning of potential sales declines while Eli Lilly projected continued sales growth [1] - Eli Lilly is expected to launch its own oral weight-loss medication in the second quarter of this year, pending FDA approval, which would introduce additional competition in the market [1] - Over the past 12 months, Hims & Hers shares have decreased by more than 40%, while Novo Nordisk shares have lost about 50% of their value, and Eli Lilly shares have increased by approximately 17% [1]

Core Insights - Eli Lilly and Company (LLY) has a market capitalization of $980.5 billion and is recognized for its diverse product lineup, particularly in the pharmaceutical sector [1] Stock Performance - LLY shares have increased by 28.7% over the past 52 weeks but have seen a decline of 2.8% year-to-date in 2026, underperforming compared to the S&P 500 Index, which returned 15.5% over the past year and increased by 1.9% in 2026 [2] - Compared to the Healthcare Select Sector SPDR ETF (XLV), which rose by 6% over the past year, LLY has outperformed but has lagged in 2026 [3] Growth Drivers - LLY became the first healthcare company to reach a $1 trillion market cap on November 21, primarily driven by its success in the weight-loss drug market, competing with Novo Nordisk [5] - The popularity of LLY's drugs, Zepbound and Mounjaro, along with promising results from a new oral weight-loss medication, have contributed to its growth [5] Earnings Expectations - For the fiscal year ending December 2025, analysts project an 82.8% year-over-year increase in adjusted EPS to $23.74, although LLY has a mixed earnings surprise history, surpassing estimates in three of the last four quarters [6] Analyst Ratings - LLY holds a consensus "Strong Buy" rating, with 22 out of 28 analysts recommending "Strong Buy," two "Moderate Buy," and four "Holds," indicating a positive shift in Wall Street's sentiment towards the stock [7] - Guggenheim analyst Seamus Fernandez maintained a "Buy" rating while slightly reducing the price target from $1163 to $1161, with a mean price target suggesting an 11.5% premium and a Street-high target indicating a 43.7% upside potential [8]

Core Insights - Healthcare stocks have rebounded, outperforming other sectors in the S&P 500, largely driven by the demand for weight-loss drugs like GLP-1 agonists and semaglutide treatments [2][4] - The FDA's recent approval of pill forms of weight-loss drugs is expected to further catalyze market growth in 2026 [2][6] - The GLP-1 drug market is projected to grow at a compound annual growth rate (CAGR) of 18.54% from 2024 to 2030, increasing its market value from $13.84 billion to $48.84 billion [3][6] Industry Performance - The healthcare sector has shown the best performance among the 11 S&P 500 sectors in the last six months, primarily due to the popularity of injectable weight-loss treatments [2] - North America leads the GLP-1 agonists market, contributing nearly 76% of total revenue [4] Company Developments - Major companies like Novo Nordisk and Eli Lilly have benefited significantly from the weight-loss drug market, with their products Ozempic, Wegovy, Zepbound, and Mounjaro driving growth [4] - Pfizer has made a strategic move into the weight-loss sector by signing a $2.1 billion licensing agreement to develop an early-stage weight-loss pill [5] Investment Opportunities - The Roundhill GLP-1 & Weight Loss ETF offers investors exposure to a diversified portfolio of companies involved in the weight-loss drug market, having gained 52% over the past year [6]

Core Insights - The U.S. FDA approved Novo Nordisk's weight-loss pill, Wegovy, which contains 25 mg of semaglutide, enhancing its competitive position against Eli Lilly [1][2] - The approval is expected to revitalize Novo's sales after a challenging year marked by declining shares and profit warnings [2] - The oral semaglutide pill is aimed at adults with obesity or overweight and related health conditions, potentially tapping into a market projected to reach $150 billion annually by the next decade [3] Company Strategy - Novo is leveraging its first-to-market advantage with the oral pill to regain market share in the U.S., where it has faced competition from Lilly [4] - The company has been preparing for the launch by building up supplies of the pill in North Carolina [5] - Novo's pricing strategy includes a starter dose priced at $149 per month for Medicare and Medicaid, with a recent reduction in the cash price for Wegovy from $499 to $349 [9] Market Dynamics - Approximately 40% of American adults are classified as obese, with around 12% currently using GLP-1 drugs [5] - Analysts predict that oral pills could capture about 20% of the weight-loss market by 2030, appealing to patients who prefer less invasive treatment options [6] - The approval of the oral pill may lead to increased patient uptake, as it addresses injection hesitancy and offers convenience [6][8] Competitive Landscape - Novo's injectable semaglutide initially struggled to meet demand, allowing Lilly to gain an edge with its Zepbound product [6] - Lilly's next-generation weight-loss pill, orforglipron, is expected to be approved soon, intensifying competition in the market [4] - The oral semaglutide requires specific administration guidelines, which may affect its adoption compared to Lilly's pill that has fewer restrictions [11]